zurück

Ibrutinib (new indication: chronic lymphocytic leukemia (CLL); first line; in combination with venetoclax)

Subject:

  • Active Substance: Ibrutinib
  • Name: Imbruvica®
  • Therapeutic area: Chronic lymphocytic leukemia (CLL)
  • Pharmaceutical company: Janssen-Cilag GmbH

 

Time table:

  • Start: 01.02.2023
  • Final decision by G-BA: 20.07.2023

 

Final decision:

  1. Without genetic risk factors, who are not suitable for therapy with FCR: No additional benefit proved
  2. Without genetic risk factors, who are suitable for therapy with FCR and adults with genetic risk factors: No additional benefit proved